Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1845
http://purl.obolibrary.org/obo/NCIT_C1845
|
|---|---|
| Preferred Name | Peginterferon Alfa-2b |
| Definitions |
A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A covalent conjugate of recombinant interferon alpha, subtype 2b, and polyethylene glycol (PEG), used as an antiviral and antineoplastic agent. The biological activity of this agent is derived from its interferon alpha-2b protein moiety. Interferons alfa bind to specific cell-surface receptors, leading to the transcription and translation of genes whose protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety lowers the clearance of interferon alpha-2b, thereby extending the duration of its therapeutic effects, but may also reduce the interferon-mediated stimulation of an immune response. (NCI04) |
|---|---|
| prefLabel | Peginterferon Alfa-2b
|
| label | Peginterferon Alfa-2b
|
| CHEBI_ID | CHEBI:63615
|
| PDQ_Closed_Trial_Search_ID | 43407
|
| code | C1845
|
| prefixIRI | NCIT:C1845
|
| in_subset |
See more
See less
|
| Display_Name | Peginterferon Alfa-2b
|
| Preferred_Name | Peginterferon Alfa-2b
|
| FDA_UNII_Code | G8RGG88B68
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C2H4NO2(C2H4O)n
|
| Maps_To | Peginterferon Alfa-2b
|
| CAS_Registry | 215647-85-1
|
| NSC Number | 720033
|
| NCI_Drug_Dictionary_ID | 43407
|
| Legacy Concept Name | PEG-Interferon_Alfa-2B
|
| type | |
| ALT_DEFINITION | A drug used to treat hepatitis C infections. It is also being studied in the treatment and prevention of cancer. It is a cytokine that is modified in the laboratory. It is a type of biological response modifier.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 43407
|
| Accepted_Therapeutic_Use_For | chronic hepatitis C; renal cell carcinoma
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C0796545
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |